PMID- 38164188
OWN - NLM
STAT- MEDLINE
DCOM- 20240103
LR  - 20240306
IS  - 1449-2288 (Electronic)
IS  - 1449-2288 (Linking)
VI  - 20
IP  - 1
DP  - 2024
TI  - The role of TNC in atherosclerosis and drug development opportunities.
PG  - 127-136
LID - 10.7150/ijbs.89890 [doi]
AB  - Tenascin C (TNC), a rich glycoprotein of the extracellular matrix, exhibits a 
      pro-atherosclerosis or anti-atherosclerosis effect depending on its location. 
      TNC, especially its C domain/isoform (TNC-C), is strongly overexpressed in 
      atherosclerotic plaque active areas but virtually undetectable in most normal 
      adult tissues, suggesting that TNC is a promising delivery vector target for 
      atherosclerosis-targeted drugs. Many delivery vectors were investigated by 
      recognizing TNC-C, including G11, G11-iRGD, TN11, PL1, and PL3. F16 and FNLM were 
      also investigated by recognizing TNC-A1 and TNC, respectively. Notably, iRGD was 
      undergoing clinical trials. PL1 not only recognizes TNC-C but also the extra 
      domain-B (EDB) of fibronectin (FN), which is also a promising delivery vector for 
      atherosclerosis-targeted drugs, and several conjugate agents are undergoing 
      clinical trials. The F16-conjugate agent F16IL2 is undergoing clinical trials. 
      Therefore, G11-iRGD, PL1, and F16 have great development value. Furthermore, 
      ATN-RNA and IMA950 were investigated in clinical trials as therapeutic drugs and 
      vaccines by targeting TNC, respectively. Therefore, targeting TNC could greatly 
      improve the success rate of atherosclerosis-targeted drugs and/or specific drug 
      development. This review discussed the role of TNC in atherosclerosis, 
      atherosclerosis-targeted drug delivery vectors, and agent development to provide 
      knowledge for drug development targeting TNC.
CI  - (c) The author(s).
FAU - Chen, Wujun
AU  - Chen W
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Wang, Yanhong
AU  - Wang Y
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Ren, Chunling
AU  - Ren C
AD  - Department of Pharmacy, Women's and Children's Hospital Afliated to Qingdao 
      University, Qingdao Women's and Children's Hospital, Qingdao, Shandong, 266000, 
      China.
FAU - Yu, Sha
AU  - Yu S
AD  - Obstetrical Department, The Affiliated Hospital of Qingdao University, Qingdao, 
      Shandong, 266003, China.
FAU - Wang, Chao
AU  - Wang C
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Xing, Jiyao
AU  - Xing J
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Xu, Jiazhen
AU  - Xu J
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Yan, Saisai
AU  - Yan S
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Zhang, Tingting
AU  - Zhang T
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Li, Qian
AU  - Li Q
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Peng, Xiaojin
AU  - Peng X
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Shao, Yingchun
AU  - Shao Y
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Zhang, Renshuai
AU  - Zhang R
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
FAU - Zhang, Daijun
AU  - Zhang D
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
AD  - Qingdao Medical College, Qingdao University, Qingdao, Shandong, 266071, China.
FAU - Xing, Dongming
AU  - Xing D
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong, 266071, China.
AD  - School of Life Sciences, Tsinghua University, Beijing, 100084, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240101
PL  - Australia
TA  - Int J Biol Sci
JT  - International journal of biological sciences
JID - 101235568
RN  - 0 (Tenascin)
RN  - 0 (Protein Isoforms)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Tenascin/genetics
MH  - *Atherosclerosis/drug therapy
MH  - Extracellular Matrix
MH  - *Plaque, Atherosclerotic/drug therapy
MH  - Protein Isoforms
PMC - PMC10750296
OTO - NOTNLM
OT  - ATN-RNA
OT  - F16
OT  - G11-iRGD
OT  - PL1
OT  - TNC
OT  - atherosclerosis
OT  - drug development
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2024/01/02 11:46
MHDA- 2024/01/03 09:41
PMCR- 2024/01/01
CRDT- 2024/01/02 03:37
PHST- 2023/09/06 00:00 [received]
PHST- 2023/10/23 00:00 [accepted]
PHST- 2024/01/03 09:41 [medline]
PHST- 2024/01/02 11:46 [pubmed]
PHST- 2024/01/02 03:37 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - ijbsv20p0127 [pii]
AID - 10.7150/ijbs.89890 [doi]
PST - epublish
SO  - Int J Biol Sci. 2024 Jan 1;20(1):127-136. doi: 10.7150/ijbs.89890. eCollection 
      2024.